60 senators urge CMS to delay overall hospital quality star ratings

In wake of the April 21 release of the overall hospital quality star ratings system developed by the Centers for Medicare & Medicaid Services (CMS), sixty senators have advised a delay “to provide the necessary time to more closely examine the star rating methodology, analyze its impact on different types of hospitals, and provide more transparent information regarding the calculation of the ratings to determine accuracy.”

The concern of the senators is that "the current Star Ratings system may not accurately take into account hospitals that treat patients with low socioeconomic status or multiple complex chronic conditions.”

They continued by writing, “we are concerned that the Star Rating system may be misleading to consumers due to flaws in the measures that underpin the ratings. Many prominent hospitals that are in the top echelon of other quality rating reports, and handle the most complex procedures and patients, may receive 1 or 2 stars (out of a possible 5), indicating that they have the poorest quality in comparison to all other hospitals.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.